Urinary Tract Infections - Pipeline Review, H1 2015

Description: Urinary Tract Infections - Pipeline Review, H1 2015

Summary

This, ‘Urinary Tract Infections - Pipeline Review, H1 2015’, provides an overview of the Urinary Tract Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in -class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Urinary Tract Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
- List of Tables
- List of Figures
- Introduction
- REPORT COVERAGE
  - Urinary Tract Infections Overview
  - Therapeutics Development
  - Pipeline Products for Urinary Tract Infections - Overview
  - Pipeline Products for Urinary Tract Infections - Comparative Analysis
  - Urinary Tract Infections - Therapeutics under Development by Companies
  - Urinary Tract Infections - Therapeutics under Investigation by Universities/Institutes
  - Urinary Tract Infections - Pipeline Products Glance
  - Late Stage Products
  - Clinical Stage Products
  - Early Stage Products
  - Urinary Tract Infections - Products under Development by Companies
  - Urinary Tract Infections - Products under Investigation by Universities/Institutes
  - Urinary Tract Infections - Companies Involved in Therapeutics Development
- Achaogen Inc.
- Adenium Biotech ApS
- AstraZeneca PLC
- ConjuGon, Inc.
- Cubist Pharmaceuticals, Inc.
- Da Volterra
- DexTech Medical AB
- FOB Synthesis, Inc.
- GlycoVaxyn AG
- Melinta Therapeutics, Inc
- Merck & Co., Inc.
- MerLion Pharmaceuticals Pte Ltd
- Nabriva Therapeutics AG
- NovaBay Pharmaceuticals, Inc.
- Nymox Pharmaceutical Corporation
- Osel Inc.
- Paratek Pharmaceuticals, Inc.
- Sequoia Sciences, Inc.
- Shionogi & Co., Ltd.
- Syntiron LLC
- Tetraphase Pharmaceuticals Inc.
- The Medicines Company
- Urinary Tract Infections - Therapeutics Assessment
  - Assessment by Monotherapy Products
  - Assessment by Combination Products
  - Assessment by Target
  - Assessment by Mechanism of Action
  - Assessment by Route of Administration
  - Assessment by Molecule Type
- Drug Profiles
  - (ceftaroline fosamil + avibactam sodium) - Drug Profile
    - Product Description
    - Mechanism of Action
    - R&D Progress
  - (ceftazidime + avibactam sodium) - Drug Profile
    - Product Description
    - Mechanism of Action
    - R&D Progress
R&D Progress
GP-4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
klebsiella pneumoniae vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LACTIN-V - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Micselon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nu-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nu-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NXB-4221 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
omadacycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plazomicin sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proteins for Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
relebactam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-649266 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit 23S Ribosomal RNA for Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Urinary Tract Infection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZTI-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Urinary Tract Infections - Recent Pipeline Updates
Urinary Tract Infections - Dormant Projects
Urinary Tract Infections - Discontinued Products
Urinary Tract Infections - Product Development Milestones
Featured News & Press Releases
Jan 08, 2015: MerLion’s Finafloxacitin Shows Positive Phase 2 Results in Complicated Urinary Tract Infections
Dec 19, 2014: FDA approves new antibacterial drug Zerbaxa
Dec 05, 2014: Anti-Infective Advisory Committee Recommends Approval Of Actavis’ Ceftazidime-Avibactam
Oct 08, 2014: Tetraphase Pharmaceuticals Announces Presentation of Data at IDWEEK on the Activity of Eravacycline Against Multidrug-Resistant Bacteria
Oct 06, 2014: Tetraphase Pharmaceuticals Announces Initiation of Pivotal Portion of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI
Sep 04, 2014: Merck’s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA
Sep 02, 2014: Tetraphase Pharmaceuticals Announces Positive Oral Dosing Data from Lead-in of IGNITE 2 Phase 3 Trial of Eravacycline in cUTI Support Advancement to Pivotal Portion
Jul 28, 2014: Tetraphase Pharmaceuticals Completes Enrollment of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections
Jul 01, 2014: GlycoVaxyn announces the initiation of a Phase I clinical trial in collaboration with Janssen for a vaccine against Extra-intestinal pathogenic Escherichia coli causing urinary tract infection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Urinary Tract Infections, H1 2015
Number of Products under Development for Urinary Tract Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Urinary Tract Infections - Pipeline by Achaogen Inc., H1 2015
Urinary Tract Infections - Pipeline by Adenium Biotech ApS, H1 2015
Urinary Tract Infections - Pipeline by AstraZeneca PLC, H1 2015
Urinary Tract Infections - Pipeline by ConjuGon, Inc., H1 2015
Urinary Tract Infections - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015
Urinary Tract Infections - Pipeline by Da Volterra, H1 2015
Urinary Tract Infections - Pipeline by DexTech Medical AB, H1 2015
Urinary Tract Infections - Pipeline by FOB Synthesis, Inc., H1 2015
Urinary Tract Infections - Pipeline by GlycoVaxyn AG, H1 2015
Urinary Tract Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015
Urinary Tract Infections - Pipeline by Merck & Co., Inc., H1 2015
Urinary Tract Infections - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2015
Urinary Tract Infections - Pipeline by Nabriva Therapeutics AG, H1 2015
Urinary Tract Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015
Urinary Tract Infections - Pipeline by Nymox Pharmaceutical Corporation, H1 2015
Urinary Tract Infections - Pipeline by Osel Inc., H1 2015
Urinary Tract Infections - Pipeline by Paratek Pharmaceuticals, Inc., H1 2015
Urinary Tract Infections - Pipeline by Sequoia Sciences, Inc., H1 2015
Urinary Tract Infections - Pipeline by Shionogi & Co., Ltd., H1 2015
Urinary Tract Infections - Pipeline by Syntiron LLC, H1 2015
Urinary Tract Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015
Urinary Tract Infections - Pipeline by The Medicines Company, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Urinary Tract Infections Therapeutics - Recent Pipeline Updates, H1 2015
Urinary Tract Infections - Dormant Projects, H1 2015
Urinary Tract Infections - Dormant Projects (Contd..1), H1 2015
Urinary Tract Infections - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Urinary Tract Infections, H1 2015
Number of Products under Development for Urinary Tract Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Urinary Tract Infections - Pipeline Review, H1 2015
Web Address: http://www.researchandmarkets.com/reports/3106225/
Office Code: SCH3Q6ZW

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>□</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>□</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>□</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World